TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03715699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Leflunomide
Description: Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Leflunomide
Description: Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months.
Study: NCT04187638

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Butter
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butter
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
Study: NCT00524342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprelvekin, Interleukin 11, IL-11
Description: 25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
Study: NCT01826110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PIB
Description: Approximately 15 mCI \[11C\]PIB IV x1
Study: NCT02431936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill made to look identical to Prazosin intervention.
Study: NCT04948775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises
Description: A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
Study: NCT01100515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normobaric oxygen therapy
Description: oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
Study: NCT03621332

Intervention type: OTHER
Intervention: Questionnaire
Description: Online/paper questionnaires
Study: NCT01422915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colestipol
Description: 2 grams morning and bedtime for 90 days.
Study: NCT01071538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
Study: NCT00784381

Intervention type: DEVICE
Intervention: computer-assisted counselling about target drugs
Description: implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value

Intervention type: DEVICE
Intervention: computer-assisted counselling about target drugs
Description: implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
Study: NCT04474795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff -Educational training
Description: Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
Study: NCT04030923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
Study: NCT01670487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant
Description: Topical stream of 4 to 10 seconds duration to skin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Topical intervention of sterile water stream 4 to 10 seconds to skin.
Study: NCT00804076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NP2
Description: Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
Study: NCT04030923

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
Study: NCT03455491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 100 mg
Description: once daily during 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 200 mg
Description: once daily during 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily during 3 days.
Study: NCT03630211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Stem Cell Mobilization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Stem Cell Mobilization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Transplantation Conditioning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Thymocyte Globulin
Description: Transplantation Conditioning
Study: NCT02331433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN1125
Description: APN1125 orally at ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01650961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.075 mg IV as bolus before induction of general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml normal saline as bolus before induction of general anesthesia
Study: NCT02505503

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unloading shoes
Description: The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unloading shoes
Description: The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unadapted control shoe
Description: During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unadapted control shoe
Description: During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
Study: NCT03073980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen for pain control during procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Acetaminophen
Description: PO Acetaminophen for pain control during procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IV Acetaminophen
Description: Placebo IV Acetaminophen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Acetaminophen
Description: Placebo IV Acetaminophen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo PO Acetaminophen
Description: Placebo PO Acetaminophen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO Acetaminophen
Description: Placebo PO Acetaminophen
Study: NCT03046485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management program 'Living with Vision Loss'
Description: group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
Study: NCT04001621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with capecitabine
Description: pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
Study: NCT03710109

Intervention type: OTHER
Intervention: EEG
Description: non-invasive, non-interventional sensor
Study: NCT00577642

Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid
Description: 4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
Study: NCT00185952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
Study: NCT03860675

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of walking-related fatigability
Description: participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of walking-related fatigability
Description: participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
Study: NCT05693636

Intervention type: PROCEDURE
Intervention: Total wrist arthroplasty
Description: Two different surgical interventions for treatment of end-stage arthritis are compared
Study: NCT01352832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive DVD
Description: An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT03949933

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton and carbon ion radiotherapy
Description: proton and carbon ion radiotherapy
Study: NCT00472264

Intervention type: PROCEDURE
Intervention: PET imaging
Description: Medical imaging assessment
Study: NCT04111640

Intervention type: OTHER
Group type: OTHER
Intervention: CoRe software
Description: Computer-supported cognitive training (CT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Paper and pencil cognitive training (paper-and-pencil CoRe version)
Study: NCT01744665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
Study: NCT03990064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musicotherapy
Description: receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
Study: NCT02799823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
Study: NCT02281032

Intervention type: OTHER
Group type: OTHER
Intervention: interRAI PC
Description: PREPARATORY PHASE~* Step 0: Introductory information~* Step 1: Training on the interRAI PC and the BelRAI webapplication~* Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~* Step 3: Identification of residents with palliative care needs, based on the surprise question~* Step 4: Informed consent signature requirements~* Step 5: Login to the BelRAI webapplication~* Step 6: Definitions of roles and functions~* Step 7: Completion of the interRAI PC~* Step 8: Interpretation of results~* Step 9: Use of results
Study: NCT05571228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-stigma intervention
Description: Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
Study: NCT03116074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Digital Health Tools
Description: Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Digital Health Tools
Description: Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos
Study: NCT05339295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
Study: NCT04599322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
Description: Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
Study: NCT03761095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unesbulin
Description: Unesbulin will be administered as per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine will be administered as per the dose and schedule specified in the arm.
Study: NCT06170424

Intervention type: PROCEDURE
Intervention: spray skin
Description: The patients who used the autologous skin cell suspension combined with skin grafting.

Intervention type: PROCEDURE
Intervention: Control group
Description: The patients who used skin grafting.
Study: NCT01550146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: iv. dexamethasone 0.1 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv. Normal Saline 0.1 ml/kg
Study: NCT04039893

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Systematic axillary ultrasound imaging
Description: Before surgery, all patients will be explored with a pre-defined systematic and reproducible axillary ultrasound imaging workflow intending to establish the number of neoplastic lymph nodes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sentinel node
Description: Sentinel nodes will be identified with a radioisotope tracer and blue dye or fluorescein.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excision of suspicious lymph nodes
Description: Nodes suspected to be infiltrated both by physical exploration and/or ultrasound will be excised and evaluated separately.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two steps axillary node clearance
Description: Axillary node clearance will be performed in two steps comprising inferior and superior clearance. The second intercostobrachial nerve will be considered the limit defining the border between superior and inferior axilla.
Study: NCT00388700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CT-01
Description: On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Leukovorin, bevacizumab
Description: On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
Study: NCT02060682

Intervention type: DEVICE
Intervention: Navvus Catheter FFR
Description: Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).